Technology News and Research

RSS

BIOCIUS and Agilent launch RF360 High Resolution System for high-throughput screening of in vitro ADME assays

BIOCIUS Life Sciences, Inc. and Agilent Technologies Inc. today announced the launch of the RF360 High Resolution System for high-throughput screening of in vitro ADME assays. Combining the accurate mass capabilities of Agilent's time-of-flight (TOF) mass spectrometers and the unprecedented sample processing speed of RapidFire® technology, the instrument revolutionizes in vitro ADME analysis by eliminating the method development bottleneck in drug discovery.

From Evident Corporation - Life Sciences 20 May 2010

Collegium Pharmaceutical receives Notice of Allowance from USPTO for DETERx technology

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that it has received Notice of Allowance from the U.S. Patent and Trademark Office for its patent application "Abuse-Deterrent Drug Formulations", US Patent Application Number 11/149,867. The Notice of Allowance is the USPTO's official communication that the Company's application has successfully completed examination and that a patent will be issued.

20 May 2010

Cato Research to provide etrials EDC solution through Merge Healthcare's technology transfer program

Merge Healthcare, a leading Health IT solutions provider, announced today that it was selected by Cato Research Ltd. to provide the proprietary etrials EDC solution through Merge's technology transfer program. This new agreement expands Merge's partnership with CATO to provide additional technology for clinical trials management, as well as extending the relationship for an additional five years.

20 May 2010

Vanderbilt University orders Bruker's AVANCE III 900 US2 NMR spectrometer

Bruker, the leader in analytical magnetic resonance instrumentation, announces a major multi-systems NMR order from Vanderbilt University, including an ultra-high field AVANCE™ III 900 US2 NMR spectrometer. This purchase was made possible in large part by the American Recovery and Reinvestment Act. Vanderbilt will use these NMR instruments for a broad range of biophysical and structural analyses in biomedical research, as well as for cancer drug discovery using fragment-based approaches and structure-based drug design.

20 May 2010

STAAR Surgical receives CE Mark approval for product improvements to Visian Implantable Collamer Lens

STAAR Surgical Company, a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced CE Mark approval for a range of product improvements to the Company's Visian Implantable Collamer® Lens (ICL™) that more than doubles the current Visian addressable market in Europe.

20 May 2010

NeuroTherapeutics Pharma closes $43 million Series B financing round

NeuroTherapeutics Pharma, Inc. (NTP), a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders, announced today that it closed a $43 million Series B financing. New investors include Fidelity Biosciences, MPM Capital and SR One, who co-led the transaction, and Pfizer, Inc. Existing investors Novo Ventures and Thomas McNerney & Partners also participated in the round.

20 May 2010

Patterson's consolidated sales for fourth-quarter fiscal 2010 up 4%

Patterson Companies, Inc. today reported consolidated sales of $812,762,000 for the fourth quarter of fiscal 2010 ended April 24, an increase of 4% from $779,884,000 in the year-earlier quarter. Internal growth accounted for 1% of the fourth quarter sales increase, with acquisitions and foreign currency adjustments accounting for the balance.

20 May 2010

Encision fourth-quarter net sales increase 3.6% to $3.19 million

Encision Inc., a medical device company owning patented surgical technology that is emerging as a standard of care in minimally-invasive surgery, reported its financial results for its fourth quarter and fiscal year ended March 31, 2010.

20 May 2010

Research and movement in future towards universal influenza virus vaccine

Researchers at Mt. Sinai School of Medicine have developed a novel influenza vaccine that could represent the next step towards a universal influenza vaccine eliminating the need for seasonal immunizations. They report their findings today in the inaugural issue of mBio-, the first online, open-access journal published by the American Society for Microbiology.

20 May 2010

MicroStockProfit.com releases investment report on Discovery Laboratories

MicroStockProfit.com announces an investment report featuring Discovery Laboratories Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

20 May 2010

Dynamic testing approach for HIV/AIDS diagnostics

A relatively simple electronic gadget could speed up HIV/AIDS diagnostics and improve accuracy particularly in parts of the world with very limited access to healthcare workers. The device is described in the International Journal of Biomedical Engineering and Technology.

20 May 2010

Androgen receptors promote hepatitis B virus in growth and development of hepatoma cells

Dr. Ming-Heng Wu of the Institute of Basic Medical Sciences at National Cheng Kung University (NCKU), Taiwan, in collaboration with Prof. Chawnshang Chang's laboratory of University of Rochester (UR), United States, have discovered that androgen receptors (AR) can promote hepatitis B virus-induced hepatocarcinogenesis through modulation of hepatitis B virus (HBV) RNA transcription.

20 May 2010

New Agilent SurePrint G3 Gene Expression Microarrays introduced

Agilent Technologies Inc. today introduced Agilent SurePrint G3 Gene Expression Microarrays, providing up to one million features per standard 1-by-3-inch slide for added throughput, unique coverage which includes both coding and non-coding RNA, and cost effectiveness.

20 May 2010

MEDRAD's Intego PET Infusion System integrated with Pinestar's Nuclear Medicine Information System

Today, MEDRAD, Inc. and Pinestar Technology, Inc. announced plans to enable data communication between MEDRAD's Intego™ PET Infusion System and Pinestar's Nuclear Medicine Information System (NMIS). The companies are closing the information gap between state of the art infusion systems and the latest information systems, and thus adding to the workflow benefits of automated FDG infusion.

20 May 2010

Trius awarded new DTRA contract for developing novel antibiotics against gram-negative bacterial pathogens

Trius Therapeutics, Inc. today announced that it has been awarded a new four and a half year contract from the Defense Threat Reduction Agency (DTRA), an agency within the U.S. Department of Defense, for the development of novel antibiotics directed against gram-negative bacterial pathogens. Trius may receive up to $29.5 million in support of development efforts under the new DTRA contract, which is funded as part of DTRA's Transformational Medical Technologies Initiative (TMTI).

20 May 2010

Quest PharmaTech net consolidated loss for 2010 increases to $517,799

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced financial and operational results for the fiscal year ended January 31, 2010.

20 May 2010

Lancet special series examines TB worldwide

The Lancet released on Wednesday a special series on tuberculosis, which includes a series of papers and comments highlighting the need for new tools, the threat posed by drug-resistant strains, results of current control efforts and other issues about TB worldwide, Agence France-Presse reports.

20 May 2010

St. Jude Medical to acquire LightLab for $90M in cash

St. Jude Medical, Inc., a global medical device company, and LightLab Imaging, Inc. today announced a definitive agreement under which St. Jude Medical will acquire LightLab, a subsidiary of Goodman Co., Ltd. for approximately $90 million in cash.

20 May 2010

UAMS and partners receive $14.7M NIH grant for extension of biomedical research

Biomedical research in Arkansas has received a $14.7 million boost over five years from the National Institutes of Health (NIH) to continue expanding and improving biomedical research in the state.

20 May 2010

Luminex, HTG launch qBead Gene Expression Assay

Luminex Corporation, the worldwide leader in multiplexed solutions, and High Throughput Genomics, Inc. (HTG), provider of the quantitative Nuclease Protection Assay (qNPA™), today launched a new custom gene expression product, the qBead Gene Expression Assay (qBead Assay). The companies co-developed the product and have signed an exclusive distribution agreement in which Luminex will begin offering it to the research community.

From Luminex 20 May 2010